Silymarin inhibits the lipogenic pathway and reduces worsening of non-alcoholic fatty liver disease (NAFLD) in mice.

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Archives of Physiology and Biochemistry Pub Date : 2024-08-01 Epub Date: 2022-11-03 DOI:10.1080/13813455.2022.2138445

Luana Cristina Faria Carvalho, Flávia Monteiro Ferreira, Bruna Vidal Dias, Daniela Couto de Azevedo, Gustavo Henrique Bianco de Souza, Matheus Marque Milagre, Marta de Lana, Paula Melo de Abreu Vieira, Cláudia Martins Carneiro, Sílvia de Paula-Gomes, Silvia Dantas Cangussu, Daniela Caldeira Costa

{"title":"Silymarin inhibits the lipogenic pathway and reduces worsening of non-alcoholic fatty liver disease (NAFLD) in mice.","authors":"Luana Cristina Faria Carvalho, Flávia Monteiro Ferreira, Bruna Vidal Dias, Daniela Couto de Azevedo, Gustavo Henrique Bianco de Souza, Matheus Marque Milagre, Marta de Lana, Paula Melo de Abreu Vieira, Cláudia Martins Carneiro, Sílvia de Paula-Gomes, Silvia Dantas Cangussu, Daniela Caldeira Costa","doi":"10.1080/13813455.2022.2138445","DOIUrl":null,"url":null,"abstract":"Context: The role of silymarin in hepatic lipid dysfunction and its possible mechanisms of action were investigated.Objective: To evaluate the effects of silymarin on hepatic and metabolic profiles in mice fed with 30% fructose for 8 weeks.Methods: We evaluated the antioxidant profile of silymarin; mice consumed 30% fructose and were treated with silymarin (120 mg/kg/day or 240 mg/kg/day). We performed biochemical, redox status, and histopathological assays. RT-qPCR was performed to detect ACC-1, ACC-2, FAS, and CS expression, and western blotting to detect PGC-1α levels.Results: Silymarin contains high levels of phenolic compounds and flavonoids and exhibited significant antioxidant capacity in vitro. In vivo, the fructose-fed groups showed increased levels of AST, ALT, SOD/CAT, TBARS, hepatic TG, and cholesterol, as well as hypertriglyceridaemia, hypercholesterolaemia, and increased ACC-1 and FAS. Silymarin treatment reduced these parameters and increased mRNA levels and activity of hepatic citrate synthase.Conclusions: These results suggest that silymarin reduces worsening of NAFLD.","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2022.2138445","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Context: The role of silymarin in hepatic lipid dysfunction and its possible mechanisms of action were investigated.

Objective: To evaluate the effects of silymarin on hepatic and metabolic profiles in mice fed with 30% fructose for 8 weeks.

Methods: We evaluated the antioxidant profile of silymarin; mice consumed 30% fructose and were treated with silymarin (120 mg/kg/day or 240 mg/kg/day). We performed biochemical, redox status, and histopathological assays. RT-qPCR was performed to detect ACC-1, ACC-2, FAS, and CS expression, and western blotting to detect PGC-1α levels.

Results: Silymarin contains high levels of phenolic compounds and flavonoids and exhibited significant antioxidant capacity in vitro. In vivo, the fructose-fed groups showed increased levels of AST, ALT, SOD/CAT, TBARS, hepatic TG, and cholesterol, as well as hypertriglyceridaemia, hypercholesterolaemia, and increased ACC-1 and FAS. Silymarin treatment reduced these parameters and increased mRNA levels and activity of hepatic citrate synthase.

Conclusions: These results suggest that silymarin reduces worsening of NAFLD.

查看原文本刊更多论文

水飞蓟素能抑制脂肪生成途径，减轻小鼠非酒精性脂肪肝（NAFLD）的恶化。

背景：研究水飞蓟素在肝脏脂质功能障碍中的作用及其可能的作用机制：研究水飞蓟素在肝脏脂质功能障碍中的作用及其可能的作用机制：评估水飞蓟素对喂食30%果糖8周的小鼠肝脏和代谢状况的影响：我们评估了水飞蓟素的抗氧化特性；小鼠摄入 30% 的果糖，并接受水飞蓟素（120 毫克/千克/天或 240 毫克/千克/天）治疗。我们进行了生化、氧化还原状态和组织病理学检测。通过RT-qPCR检测ACC-1、ACC-2、FAS和CS的表达，通过Western印迹检测PGC-1α的水平：结果：水飞蓟素含有大量酚类化合物和类黄酮，在体外具有显著的抗氧化能力。在体内，果糖喂养组的 AST、ALT、SOD/CAT、TBARS、肝脏 TG 和胆固醇水平升高，并出现高甘油三酯血症、高胆固醇血症、ACC-1 和 FAS 升高。水飞蓟素治疗降低了这些参数，并提高了肝柠檬酸合成酶的 mRNA 水平和活性：这些结果表明，水飞蓟素可减少非酒精性脂肪肝的恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.